Dr. Salah Al Janabi Joins Agiomix as Managing Director
24th September 2019
Agiomix board of directors has announced the appointment of a new managing director; Dr. Salah Al Janabi, a prominent scientist, and a seasoned senior manager with over 30 years of management experience of healthcare institutions. Over his life long career, Dr. Salah Al Janabi has helped establish and run many medical institutions including polyclinics, hospitals and pathology labs. Amongst the roles he held was his role at the Apollo Bramwell Hospital in Mauritius as the Deputy Chief Medical Officer, where he helped lead the hospital through the Joint Commission International (JCI) and ISO 15189 accreditation, he also established new services and units at the hospital including a Stem Cell therapy unit, a Fertility Center, and a Mother & Child Centre of Excellence.
Dr. Al Janabi holds a Doctorate degree in Molecular Genetics from Iowa State University and has many publications across renowned scientific journals.
“We believe that Agiomix is now ready for this important appointment after it established its state-of-the-art labs and received local accreditation, Dr. Salah will provide distinguished leadership to the institution and will give all the investors the comfort level they need to continue to support this ambitious venture”, said Mr. Jaffer Patel, shareholder and board member of Agiomix FZ-LLC.
Dr. Salah Al Janabi said, “I’m quite excited to join Agiomix. I admire the company’s vision and can see the great scope of opportunities it can realize. I intend to make a substantial refinement to the company’s strategies and business culture to place it amongst the best genetics services providers in the world.”
Dr Clarkson joins Agiomix with 20 years’ experience of developing commercial diagnostics and life science tools.
August 7th 2018
Agiomix, the next generation genomics company, has announced the appointment of Dr John Clarkson as chairman with immediate effect.
Dr Clarkson joins Agiomix with 20 years’ experience of developing commercial diagnostics and life science tools. He has held a number of senior commercial and technical leadership positions within both public and private companies.
Most recently, Dr Clarkson was the founding CEO of the molecular diagnostics company, Atlas Genetics, where he remains a non-executive director. During his tenure at Atlas Genetics, Dr Clarkson raised $90 million with multiple fundraising to fund the development of the rapid io diagnostic platform for infectious diseases from concept through to regulatory approval.
Dubai, UAE, – Agiomix, the next generation genomics company announced that Dr. Walid Dridi has joined its Medical Board as of June 2019.
“As part of Agiomix’s strategy to attract talented specialists to join its team, we are glad to announce that Dr.Walid Dridi will join our Board of Medical Directors. Dr. Dridi’s experience in running world-class genomics service laboratories will add a wealth to Agiomix capabilities and standards, and his background in cytogenetics will allow Agiomix to offer detailed and comprehensive medical reports to patients and partner laboratories across the region that match the industry’s highest standards”, said Dr. John Clarkson, Board Director of Agiomix.
Agiomix Appoints Dr. Cengiz Yakicier as a Senior Member of its Medical Board
Dubai, UAE – Agiomix, the next generation genomics company has announced the appointment of a leading physician-scientist, Dr. Cengiz Yakicier to the position of Medical Director with immediate effect. As a member of Agiomix medical board Dr. Cengiz will be responsible for developing and executing on the company’s medical strategy to drive genomic analysis across healthcare practices in the region.
“We are very excited to welcome Dr. Cengiz to our team of medical experts. This is a transformative time in the evolution of precision and translational medicine and Dr. Cengiz will add a lot to our services to the healthcare community” said Dr. John Clarkson Board Director of Agiomix FZ-LLC.
Dubai, UAE, – Agiomix FZ-LLC; the next generation sequencing and molecular genetics lab in Dubai received its Dubai Health Authority (DHA) license on 18th June 2019, the lab at the Dubai Science Park was inspected by the DHA team for quality and compliance with the DHA licensing requirements and was found to be in conformance with all the required policies, guidelines and regulations to receive the DHA license.